October 28, 2019
1 min watch
Save

VIDEO: Improvements maintained for 2 years with abicipar for wet AMD

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

SAN FRANCISCO — Rahul Khurana, MD, of Northern California Retina Vitreous Associates, shared the 2-year results from the CEDAR and SEQUOIA studies, which showed abicipar given every 12 weeks and every 8 weeks was equivalent to ranibizumab every 4 weeks for neovascular age-related macular degeneration at the American Academy of Ophthalmology annual meeting.

“The impressive aspect of the study was the visual gains seen in the first years were maintained with only four treatments in the abicipar every 12-week arm,” he said. “There were improvements in visual acuity and the retinal thickness were maintained through 2-year study trial.”

Disclosure: Khurana reports consulting for and receiving grant support from Allergan.